Xiaoxue Zhu

发表

Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selection

Xiao-ying Li, Dalong Zhu, Yongguo Li, 2018, Diabetes, obesity & metabolism.

Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals

J. Niu, Xiaojiao Li, Hong Zhang, 2021, Expert opinion on investigational drugs.

Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-Deficiency Anemia.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2021, Annals of medicine.

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

X. Yang, Xiaojiao Li, Hong Zhang, 2021, Frontiers in Pharmacology.

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection

J. Niu, Xiaojiao Li, Hong Zhang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study

Huimao Zhang, J. Niu, Lei Zhang, 2022, Hepatology International.

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus

J. Niu, Xiaojiao Li, Hong Zhang, 2018, The Journal of pharmacy and pharmacology.

HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial

Qianqian Wang, Yanhua Ding, Liang Zhou, 2023, Investigational New Drugs.

Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, in Chinese people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy Individuals at Steady State.

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Clinical therapeutics.

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, Diabetes, obesity & metabolism.

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers

Haijing Wei, Yanhua Ding, Binhua Lv, 2020, Frontiers in Pharmacology.

Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2020, CNS Drugs.